SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " platelet " 8 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Hot Summer Drop: (plated) Skin Science’s BODY Serum
(plated ) Skin Science is rolling out its BODY Serum, extending the skincare platform beyond the face for the first time. BODY Serum features the brand’s proprietary platelet-derived Renewosome technology. “Consumers shouldn’t have to accept that advanced skincare stops at the jawline,” says Alisa Lask, Chief Executive Officer of Rion Aesthetics, in a news release. […]
RWJBarnabas Health Urges Community to Donate Blood Amid National Shortage
RWJBarnabas Health is asking the public to donate blood and platelets as New Jersey and the nation faces a growing blood shortage driven by a significant decline in donor turnout and overall collections.
New Treatment at UToledo Health Uses Patient’s Blood Cells to Accelerate Healing
A concentrated solution of the patient's own blood platelets is injected to encourage accelerated healing in a specific area of the body.
Routine testing is needed to locate patients who may not benefit from clopidogrel
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset. The Big Pharma had been evaluating the therapy, dubbed PF-06835375, in a phase 2 study of 61 patients with primary immune thrombocytopenia (ITP) that kicked off in 2022, according to the federal trials register. However, Pfizer confirmed to Fierce on Monday that this study had been terminated “due to a business decision.” “The decision to terminate the trial was not based on any safety concerns,” a spokesperson pointed out. At time of publication, PF-06835375 remained listed on Pfizer’s website for both ITP and lupus. A phase 1 study in lupus wrapped up in 2022, according to the trials database. ITP is an autoimmune disorder characterized by a low platelet count. Novartis was at one point evaluating its B-cell-depleting antibody ianalumab—recently approved as Fabhalta to treat immunoglobulin A nephropathy—as a potential treatment ITP. But the therapy struggled to demonstrate a benefit in the clinic for this indication. When contacted by Fierce, Pfizer wouldn’t confirm whether all work on PF-06835375 has been halted, and whether the company has any other plans to explore C-X-C chemokine receptor type 5 (CXCR5) as a mechanism. CXCR5 is found in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma chemokine receptor. However, there is little expression in normal tissue, which has led some drug developers to explore its potential. Vincerx Pharma had at one point been planning to take an anti-CXCR5 ADC into the clinic to treat B-cell malignancies, but that ambition was scrapped due to cash constraints. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: [ ](https://qtxasset.com/quartz/qcloud5/media/image/where_big_pharma_is_placing_its_bets.png?VersionId=B8JrRbJ.pFUSK1pJgjeWHLGm_18RdLAy)
UF Health to host seminars on platelet-rich plasma therapy and brain tumor care
Seminar to be held on Wednesday at Hilton University of Florida Conference Center.
NCSHP helicopter delivers critical blood platelets to ECU Health amid North Carolina snowstorm
Heavy snowfall in North Carolina blocked road deliveries of critical blood platelets, leaving ECU Health in Greenville facing an urgent supply shortage.
Prasugrel after PCI outperforms other common antiplatelet drugs
"Prasugrel provided the optimal balance between efficacy and safety," researchers noted in a new meta-analysis.